Guardant Health Inc. (GH) shares soared 8.64% in pre-market trading on Thursday following the company's release of impressive first-quarter 2025 financial results and an upward revision of its full-year revenue guidance.

The precision oncology company reported a narrower-than-expected Q1 loss of $0.49 per share, significantly beating analyst estimates of $0.56. Revenue for the quarter came in at $203.5 million, surpassing Wall Street expectations of $190.1 million and marking a robust 20.76% increase compared to the same period last year. The strong performance was driven by growth across all business segments, with oncology revenue up 20% to $150.6 million and biopharma and data revenue increasing 21% to $45.4 million.

In light of the strong Q1 results, Guardant Health raised its full-year 2025 revenue guidance to a range of $880 million to $890 million, up from the previous range of $850 million to $860 million. This updated outlook, representing a year-over-year growth of 19% to 20%, exceeded analyst expectations and likely contributed to the positive investor sentiment. The company's progress in its screening business, with 9,000 Shield screening tests performed during the quarter, also showed promise for future growth. Following the earnings report, several analysts raised their price targets for Guardant Health, including Canaccord Genuity (to $65 from $60), Leerink Partners (to $65 from $55), and Barclays (to $60 from $55), further boosting investor confidence.